Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery

PURPOSE: Given the lack of evidence of the effect of bariatric surgery (BS) on atherogenic dyslipidemia (AD), which is a characteristic of obese subjects, this study aimed to describe the remission rate of AD 1 year after BS in severely obese patients. MATERIALS AND METHODS: A non-randomised, prospe...

Descripción completa

Detalles Bibliográficos
Autores: Climent, Elisenda, Benaiges Foix, David, Pedro-Botet, Juan, Flores Le Roux, Juana Antonia, Ramón Moros, José Manuel, Villatoro Moreno, Montserrat, Fontane Francia, Laia, Chillarón Jordan, Juan José, Goday Arnó, Albert
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2017
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/33818
Acceso en línea:http://hdl.handle.net/10230/33818
http://dx.doi.org/10.1007/s11695-016-2504-6
Access Level:acceso abierto
Palabra clave:Obesitat mòrbida
Obesitat -- Cirurgia
Atherogenic dyslipidemia
Atherogenic index
Bariatric surgery
id ES_a42e49d96be7e59fda90625b6e3eaf11
oai_identifier_str oai:recercat.cat:10230/33818
network_acronym_str ES
network_name_str España
repository_id_str
spelling Atherogenic Dyslipidemia Remission 1 Year After Bariatric SurgeryCliment, ElisendaBenaiges Foix, DavidPedro-Botet, JuanFlores Le Roux, Juana AntoniaRamón Moros, José ManuelVillatoro Moreno, MontserratFontane Francia, LaiaChillarón Jordan, Juan JoséGoday Arnó, AlbertObesitat mòrbidaObesitat -- CirurgiaAtherogenic dyslipidemiaAtherogenic indexBariatric surgeryPURPOSE: Given the lack of evidence of the effect of bariatric surgery (BS) on atherogenic dyslipidemia (AD), which is a characteristic of obese subjects, this study aimed to describe the remission rate of AD 1 year after BS in severely obese patients. MATERIALS AND METHODS: A non-randomised, prospective cohort study was conducted in patients undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy with a 1-year follow-up. AD was defined as triglycerides ≥1.71 mmol/l or treatment with fibrates and low high-density lipoprotein (HDL) cholesterol (<1.03 mmol/l in men or <1.3 mmol/l in women). RESULTS: AD was present in 81 (22.8%) of the 356 patients; these were more frequently men and presented higher total cholesterol and non-HDL cholesterol concentrations. AD remission rate was 74.1% at 3 months, 90.1% at 6 months and 96.3% at 12 months, respectively, after BS. In this group of patients, HDL cholesterol levels rose progressively (1.0 ± 0.2 to 1.5 ± 0.3 mmol/l, p < 0.001) and triglycerides decreased (2.5 ± 0.9 to 1.2 ± 0.5 mmol/l, p < 0.001) during follow-up. Regarding previous lipid-lowering therapy, fibrates and ezetimibe were withdrawn in all patients and statins in 69.4% 1 year after surgery. CONCLUSION: BS has beneficial effects on lipid profile, achieving complete remission of AD at 1 year of follow-up in almost all patients.Springer20182017info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/33818http://dx.doi.org/10.1007/s11695-016-2504-6reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésObesity Surgery. 2017 Jun;27(6):1548-53© Springer The final publication is available at Springer via http://dx.doi.org/10.1007/s11695-016-2504-6info:eu-repo/semantics/openAccessoai:recercat.cat:10230/338182026-05-29T05:05:01Z
dc.title.none.fl_str_mv Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
title Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
spellingShingle Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
Climent, Elisenda
Obesitat mòrbida
Obesitat -- Cirurgia
Atherogenic dyslipidemia
Atherogenic index
Bariatric surgery
title_short Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
title_full Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
title_fullStr Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
title_full_unstemmed Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
title_sort Atherogenic Dyslipidemia Remission 1 Year After Bariatric Surgery
dc.creator.none.fl_str_mv Climent, Elisenda
Benaiges Foix, David
Pedro-Botet, Juan
Flores Le Roux, Juana Antonia
Ramón Moros, José Manuel
Villatoro Moreno, Montserrat
Fontane Francia, Laia
Chillarón Jordan, Juan José
Goday Arnó, Albert
author Climent, Elisenda
author_facet Climent, Elisenda
Benaiges Foix, David
Pedro-Botet, Juan
Flores Le Roux, Juana Antonia
Ramón Moros, José Manuel
Villatoro Moreno, Montserrat
Fontane Francia, Laia
Chillarón Jordan, Juan José
Goday Arnó, Albert
author_role author
author2 Benaiges Foix, David
Pedro-Botet, Juan
Flores Le Roux, Juana Antonia
Ramón Moros, José Manuel
Villatoro Moreno, Montserrat
Fontane Francia, Laia
Chillarón Jordan, Juan José
Goday Arnó, Albert
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Obesitat mòrbida
Obesitat -- Cirurgia
Atherogenic dyslipidemia
Atherogenic index
Bariatric surgery
topic Obesitat mòrbida
Obesitat -- Cirurgia
Atherogenic dyslipidemia
Atherogenic index
Bariatric surgery
description PURPOSE: Given the lack of evidence of the effect of bariatric surgery (BS) on atherogenic dyslipidemia (AD), which is a characteristic of obese subjects, this study aimed to describe the remission rate of AD 1 year after BS in severely obese patients. MATERIALS AND METHODS: A non-randomised, prospective cohort study was conducted in patients undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy with a 1-year follow-up. AD was defined as triglycerides ≥1.71 mmol/l or treatment with fibrates and low high-density lipoprotein (HDL) cholesterol (<1.03 mmol/l in men or <1.3 mmol/l in women). RESULTS: AD was present in 81 (22.8%) of the 356 patients; these were more frequently men and presented higher total cholesterol and non-HDL cholesterol concentrations. AD remission rate was 74.1% at 3 months, 90.1% at 6 months and 96.3% at 12 months, respectively, after BS. In this group of patients, HDL cholesterol levels rose progressively (1.0 ± 0.2 to 1.5 ± 0.3 mmol/l, p < 0.001) and triglycerides decreased (2.5 ± 0.9 to 1.2 ± 0.5 mmol/l, p < 0.001) during follow-up. Regarding previous lipid-lowering therapy, fibrates and ezetimibe were withdrawn in all patients and statins in 69.4% 1 year after surgery. CONCLUSION: BS has beneficial effects on lipid profile, achieving complete remission of AD at 1 year of follow-up in almost all patients.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/33818
http://dx.doi.org/10.1007/s11695-016-2504-6
url http://hdl.handle.net/10230/33818
http://dx.doi.org/10.1007/s11695-016-2504-6
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Obesity Surgery. 2017 Jun;27(6):1548-53
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415476261552128
score 15,812429

Similares en LA Referencia